Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$169.75
+1.1%
$175.34
$130.96
$182.89
$300.57B0.585.57 million shs697,564 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$739.63
+1.1%
$763.83
$370.68
$800.78
$702.77B0.343.03 million shs394,414 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$127.34
+0.3%
$126.21
$99.14
$133.10
$322.56B0.388.22 million shs1.70 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.34
+0.3%
$27.08
$25.23
$40.37
$149.15B0.6141.85 million shs4.77 million shs
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+0.92%+3.88%-5.89%+0.26%+3.40%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.69%-2.65%-5.10%+16.20%+89.83%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.92%+0.59%+2.49%+5.91%+10.03%
Pfizer Inc. stock logo
PFE
Pfizer
+1.00%+1.39%-4.02%-7.63%-34.69%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.9012 of 5 stars
2.45.04.23.92.42.52.5
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8274 of 5 stars
2.44.02.54.02.42.53.1
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.8605 of 5 stars
2.35.03.34.13.92.51.9
Pfizer Inc. stock logo
PFE
Pfizer
4.99 of 5 stars
3.25.04.24.82.01.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.77
Moderate Buy$177.434.52% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$728.05-1.57% Downside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.58
Moderate Buy$131.253.07% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3337.94% Upside

Current Analyst Ratings

Latest MRK, ABBV, PFE, and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
4/8/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$140.00 ➝ $143.00
4/5/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/3/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
4/2/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$675.00 ➝ $895.00
4/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/28/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$139.00 ➝ $142.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$54.32B5.53$16.14 per share10.52$5.78 per share29.37
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B20.59$7.77 per share95.24$11.44 per share64.65
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$60.12B5.37$3.08 per share41.35$14.85 per share8.58
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.55$3.01 per share8.74$15.81 per share1.67

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$2.7362.1813.982.148.95%162.28%14.62%4/26/2024 (Confirmed)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$5.80127.5239.981.5815.36%51.22%9.94%4/30/2024 (Confirmed)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$365M$0.14909.5712.891.630.61%9.33%3.61%4/25/2024 (Confirmed)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3673.179.511.173.62%10.88%4.91%5/1/2024 (Confirmed)

Latest MRK, ABBV, PFE, and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
4/30/2024N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.61N/A-$2.61N/AN/AN/A  
4/26/2024N/A
AbbVie Inc. stock logo
ABBV
AbbVie
$2.20N/A-$2.20N/AN/AN/A  
4/25/2024N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.12N/A-$2.12N/AN/AN/A  
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    
2/2/202412/31/2023
AbbVie Inc. stock logo
ABBV
AbbVie
$2.76$2.79+$0.03$5.12$14.02 billion$14.30 billion    
2/1/2024Q4 2023
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.09$0.03+$0.12$0.54$14.49 billion$14.63 billion    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.65%+7.84%227.11%52 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.70%+15.15%89.66%10 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.082.42%+6.08%2,200.00%13 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.38%+2.57%466.67%15 Years

Latest MRK, ABBV, PFE, and LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/15/2024
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.553.54%4/12/20244/15/20245/15/2024
1/23/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.772.6%3/14/20243/15/20244/5/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
5.02
0.87
0.76
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.69
0.94
0.73
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.89
1.25
1.00
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.09%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.16 million948.93 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
72,0002.53 billion2.53 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

MRK, ABBV, PFE, and LLY Headlines

SourceHeadline
RWA Wealth Partners LLC Buys 193,726 Shares of Pfizer Inc. (NYSE:PFE)RWA Wealth Partners LLC Buys 193,726 Shares of Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 23 at 9:38 AM
Better Buy: Pfizer vs. Viking TherapeuticsBetter Buy: Pfizer vs. Viking Therapeutics
fool.com - April 23 at 9:15 AM
Pfizer vs Moderna battle over COVID vaccine patents begins in UKPfizer vs Moderna battle over COVID vaccine patents begins in UK
finance.yahoo.com - April 23 at 7:37 AM
Pfizer vs Moderna battle over COVID vaccine patents begins in UKPfizer vs Moderna battle over COVID vaccine patents begins in UK
reuters.com - April 23 at 7:21 AM
New York State Common Retirement Fund Has $281.24 Million Position in Pfizer Inc. (NYSE:PFE)New York State Common Retirement Fund Has $281.24 Million Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 22 at 9:33 PM
Pfizer (PFE) Rises Higher Than Market: Key FactsPfizer (PFE) Rises Higher Than Market: Key Facts
zacks.com - April 22 at 6:51 PM
3 Blue-Chip Stocks That Will Beat Index Returns Over the Next 3 Years3 Blue-Chip Stocks That Will Beat Index Returns Over the Next 3 Years
investorplace.com - April 22 at 5:44 PM
EC approval for Pfizer’s Emblaveo in multidrug-resistant infectionsEC approval for Pfizer’s Emblaveo in multidrug-resistant infections
thepharmaletter.com - April 22 at 3:24 PM
Pfizers Emblaveo Gets EU Marketing Authorization For Serious Infectious DiseasePfizer's Emblaveo Gets EU Marketing Authorization For Serious Infectious Disease
markets.businessinsider.com - April 22 at 3:24 PM
EU regulators approve Pfizer antibiotic EmblaveoEU regulators approve Pfizer antibiotic Emblaveo
seekingalpha.com - April 22 at 3:24 PM
Pfizer (NYSE:PFE) Stock Price Up 1.1%Pfizer (NYSE:PFE) Stock Price Up 1.1%
marketbeat.com - April 22 at 1:55 PM
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment OptionsEuropean Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
finance.yahoo.com - April 22 at 8:35 AM
European Commission Approves Pfizers EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment OptionsEuropean Commission Approves Pfizer's EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
businesswire.com - April 22 at 8:08 AM
Brendel Financial Advisors LLC Buys New Position in Pfizer Inc. (NYSE:PFE)Brendel Financial Advisors LLC Buys New Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 21 at 6:22 PM
Pfizer (NYSE:PFE) Trading 0.9% Higher Pfizer (NYSE:PFE) Trading 0.9% Higher
americanbankingnews.com - April 21 at 3:56 AM
abrdn plc Grows Stake in Pfizer Inc. (NYSE:PFE)abrdn plc Grows Stake in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 20 at 12:11 PM
3 Stocks Under $50 You Can Buy Hand Over Fist Right Now3 Stocks Under $50 You Can Buy Hand Over Fist Right Now
fool.com - April 20 at 5:50 AM
Palouse Capital Management Inc. Grows Position in Pfizer Inc. (NYSE:PFE)Palouse Capital Management Inc. Grows Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 19 at 9:47 PM
Pfizer Stock (NYSE:PFE), Analyst Ratings, Price Targets, PredictionsPfizer Stock (NYSE:PFE), Analyst Ratings, Price Targets, Predictions
benzinga.com - April 19 at 7:53 PM
ProSource360 wins opportunity to partner with Pfizer through its Diverse OnDemand MarketplaceProSource360 wins opportunity to partner with Pfizer through its Diverse OnDemand Marketplace
finance.yahoo.com - April 19 at 2:53 PM
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending StockHere is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
zacks.com - April 19 at 10:05 AM
6 Left For Dead Blue Chip Dividend Stocks Could Rally Big This Summer6 Left For Dead Blue Chip Dividend Stocks Could Rally Big This Summer
247wallst.com - April 19 at 9:41 AM
6 Left For Dead Blue Chip Dividend Stocks Could Rally Big This Summer6 Left For Dead Blue Chip Dividend Stocks Could Rally Big This Summer
247wallst.com - April 19 at 9:41 AM
Unveiling Pfizers Potent Cocktail: Key Drivers Of Free Cash Flow GrowthUnveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth
seekingalpha.com - April 19 at 7:03 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Merck & Co., Inc. logo

Merck & Co., Inc.

NYSE:MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.